1. Introduction {#s0005}
===============

Peptides are becoming an important class of molecules in the biomedical and pharmaceutical fields owing to their high affinity, strong selectivity for their targets and low toxicity [@bib1]. Despite potential limitations such as overall low oral bio-availability, low metabolic resistance, potential immunogenicity, poor membrane permeability and financial aspects, several peptide drugs have entered the market [@bib2], [@bib3]. The promising future of peptide therapeutics is further highlighted by the number of peptides in clinical and preclinical phases [@bib4]. In 2012, approximately 200 peptides entered the clinical phase, while another 400 were at advanced preclinical stages [@bib4], [@bib5], [@bib6].

Quorum sensing peptides are a group of peptides currently attracting high interest. Quorum sensing, the process of cell-to-cell communication between bacteria, has been the subject of a great number of scientific research papers [@bib7], [@bib8], [@bib9]. Three main groups of quorum sensing molecules can be distinguished: *N*-acylhomoserine lactone derivatives (AHL or auto-inducer-1), quorum sensing peptides and boron-furan derivatives (auto-inducer-2). The quorum sensing peptides, mainly found in Gram-positive bacteria, show a large structural diversity: short, linear fragments as well as cyclic (thiolacton) derivatives, with or without post-translational isoprenyl modifications, are observed [@bib10]. These peptides bind to (i) bacterial membrane associated receptors, or (ii) cytoplasmatic receptors, after which the transcription of the target genes is activated. Interfering with this bacterial quorum sensing pathway might open interesting application perspectives.

Chemical peptide synthesis for medicinal purposes has become economically viable [@bib11]. The possibility to produce small, medium (5--20 residues) to large (20--50 residues) peptides has evolved dramatically, hereby frequently outperforming the biotechnological approaches as they are known to date [@bib6]. In 1965, Merrifield cleared the way for Solid-Phase Peptide Synthesis (SPPS), thus introducing and facilitating a totally new concept in peptide synthesis [@bib12]: a peptidic chain, fixed to a solid support, is created by the consecutive addition of the appropriate amino acids. The reaction can be automated and possible solubilization-issues are avoided due to the fixation of the peptide to the solid matrix [@bib13]. During SPPS, different side-reactions can occur, resulting in several types of peptide impurities [@bib14]: *e.g*. (i) diketopiperazine structures [@bib15], [@bib16], (ii) aspartimide residues [@bib17], [@bib18], [@bib19], (iii) cysteine racemization [@bib16], (iv) diastereoisomeric products [@bib20], [@bib21], (v) dimers [@bib22], (vi) acid precursors and protected sequences [@bib20], (vii) oxidation and reduction of amino acids [@bib19], [@bib23], (viii) amino acid deletions [@bib15], [@bib23], [@bib24], [@bib25], [@bib26], (ix) amino acid insertions [@bib23], [@bib24], (x) products of side chain reactivity and (xi) amino acid modifications during cleavage [@bib16], [@bib19], [@bib23], [@bib24], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30]. Thus, the crude peptides obtained from SPPS mostly will contain many by-products. These impurities, if present even after purification, have to be quantified and characterized to meet pharmaceutical regulatory requirements, but they need to be under control as well during the unregulated biomedical research and discovery phases [@bib31], [@bib32]. Due to budgetary constraints, peptides used in research are often purchased at undefined or low purity levels, *e.g*. 70.0% [@bib31]. Generally, the peptide purity used for biomedical research and discovery purposes ranges from as low as 50.0% to more than 95.0% [@bib22], [@bib26]. However, closely related impurities of the target peptide may possess stronger binding affinities compared to the native peptide [@bib26], thus potentially causing erroneous conclusions. Investigations by de Beukelaar et al. \[[@bib33]\] indicated different immune responses of a protein-spanning peptide pool of 70.0% pure peptides due to the impurities. False-positive results in a HIV-vaccine trial were also ascribed to impurities in the peptide-mixtures [@bib34]. Zhang et al. [@bib35] were unable to reproduce their initial obestatin results in vitro, possibly due to impurities present in the initially examined peptide. Additionally, Verbeken et al. [@bib31] observed different biofunctional responses in a set of tissue-organ bath experiments caused by impurities of the examined peptides. Impurities are thus able to potentially mask biomedical experimental outcomes and may cause false negative or positive results.

Quorum sensing peptides are currently being actively investigated, *i.e*. for their possible role in the crosstalk between the microbiome and its host [@bib36], [@bib37]. Therefore, a thorough in-house QC analysis of a selected set of quorum sensing peptides will be conducted, followed by identification of the observed impurities. These data not only demonstrate the need for routine QC in peptide research, but also can help in building a global overview of expected related impurities in peptides.

2. Materials and methods {#s0010}
========================

2.1. Chemicals and reagents {#s0015}
---------------------------

A set of 98 representative peptides was selected from the Quorumpeps database [@bib38]. Linear peptide synthesis was conducted by an international supplier, while another supplier synthesized the cyclic peptides, both by means of Fmoc-SPPS. A minimal purity of 95.0% was requested at order. The sequences of the 98 peptides are provided in [Table 1](#t0005){ref-type="table"}. Acetonitrile of HPLC--MS and UPLC-MS grades were purchased from Fisher Scientific (Aalst, Belgium). Formic acid (LC--MS grade) and DMSO (p.a.≥99.9%) were obtained from Sigma-Aldrich (Diegem, Belgium). Trifluoroacetic acid (TFA), NaH~2~PO~4~·H~2~0 and Na~2~HPO~4~ were purchased from Merck (Overijse, Belgium). Water was purified using an Arium 611 purification system (Sartorius, Gottingen, Germany) yielding≥18.2 MΩ cm quality water. Eppendorf Protein LoBind 2.0 and 1.5 mL tubes were purchased from Eppendorf (Nijmegen, the Netherlands). UPLC/HPLC vials and inserts were purchased from Waters (Milford, MA, USA). The Vydac Everest C~18~ (250 mm×4.6 mm, 5 µm) column and Alltech Prevail Organic Acid column (250 mm×4.6 mm, 5 µm), both protected with guard columns, were obtained from Grace (Deerfield, IL, USA). The Acquity UPLC BEH300 C~18~ column (100 mm×2.1 mm, 1.7 µm) with guard column was purchased from Waters (Milford, MA, USA).Table 1Peptides information.Quorumpeps IDSequenceMolecular weightSolventColumn[a](#tbl1fna){ref-type="table-fn"}Purity (%)[b](#tbl1fnb){ref-type="table-fn"}2FNTIPSY839.95WaterC~18~-FA83.315Ac-CGSLF, thiolacton linkage between C1 and F5549.72Water+50% DMSOC~18~-FA88.307FNTWPSY913.00WaterC~18~-FA98.4610ADLPFEF837.93WaterC~18~-FA99.2011AGTKPQGKPASNLVECVFSLFKKCN2667.14WaterC~18~-FA72.9313AIFILAS733.91Water+58% DMSOC~18~-FA97.8214AITLIFI790.01Water+60% DMSOC~18~-FA72.4815AKDEH598.61WaterC~18~-TFA69.2616AKTVQ545.64WaterC~18~-TFA96.2017ALILTLVS829.05Water+60% DMSOC~18~-FA94.4318ARNQT588.62WaterOrganic Acid92.3319NNWNN660.64WaterC~18~-TFA92.6622CVGIW, thiolacton linkage between C1 and W5558.78Water+50% DMSOC~18~-FA60.3924CTFTLPGGGGVCTLTSECIC1962.3Water+1% DMSOC~18~-FA12.2125CVFSLFKKCN1188.47WaterC~18~-FA47.9228DIRHRINNSIWRDIFLKRK2480.91WaterC~18~-FA93.6830DLRGVPNPWGWIFGR1770.03WaterC~18~-FA91.6231DLRNIFLKIKFKKK1791.26WaterC~18~-FA76.7432DMCNGYF, thiolacton linkage between C3 and F7831.04Water+50% DMSOC~18~-FA58.0534DRVGA516.55WaterC~18~-TFA98.3040DSVCASYF, thiolacton linkage between C4 and F8873.06Water+50% DMSOC~18~-FA31.6142DWRFLNSIRDLIFPKRK2204.61WaterC~18~-FA97.8644EKMIG576.71WaterC~18~-FA99.4145EMRISRIILDFLFLRKK2178.71WaterC~18~-FA81.9146EMRKSNNNFFHFLRRI2109.44WaterC~18~-FA96.4347EMRLPKILRDFIFPRKK2187.72WaterC~18~-FA98.4649EQLSFTSIGILQLLTIGTRSCWFFYCRY3346.92Water+17% DMSOC~18~-FA52.5850ERGMT592.67WaterC~18~-TFA98.7651ERNNT632.63WaterOrganic Acid98.2452ERPVG556.62WaterC~18~-TFA99.7553ESRLPKILLDFLFLRKK2116.62WaterC~18~-FA65.1154ESRLPKIRFDFIFPRKK2177.62WaterC~18~-FA99.3055ESRVSRIILDFLFQRKK2135.54WaterC~18~-FA96.9056VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP4969.46WaterC~18~-FA33.5758DSRIRMGFDFSKLFGK1904.22WaterC~18~-FA95.7262ESRISDILLDFLFQRKK2108.47WaterC~18~-FA99.2771QNCPNIFGQWM, lacton linkage between S3 and M111319.70Water+50% DMSOC~18~-FA77.6475SINSQIGKATSNLVECVFSLFKKCN2731.2WaterC~18~-FA30.0376SNLVECVFSLFKKCN1731.06WaterC~18~-FA80.6381FNTIPKY881.04WaterC~18~-FA99.2982NTIPKY733.87WaterC~18~-FA69.2284FFNTCPSY978.09WaterC~18~-FA96.5485FNTCPSY830.91WaterC~18~-FA92.9892FHWWQTSPAHFS1530.66WaterC~18~-FA99.5493FLVMFLSG913.14Water+33% DMSOC~18~-FA91.3197QNSPNIFGQWM, lacton linkage between S3 and M111303.63Water+50% DMSOC~18~-FA43.9599GKAEF550.61WaterC~18~-FA99.33100GKATSSISKCVFSFFKKC1968.36Water+33% DMSOC~18~-FA28.65101GLWEDILYSLNIIKHNNTKGLHHPIQL3167.67WaterC~18~-FA96.92102GLWEDLLYNINRYAHYIT2254.53Water+33% DMSOC~18~-FA97.98103GNWNN603.59WaterC~18~-FA97.70105GSQKGVYASQRSFVPSWFRKIFRN2846.25WaterC~18~-FA99.31107GVNACSSLF, thiolacton linkage between C5 and F9879.13Water+50% DMSOC~18~-FA39.15111GWWEDFLYRFNIIEQKNTKGFYQPIQL3434.91Water+50% DMSOC~18~-FA89.72121ILSGAPCIPW1056.29WaterC~18~-FA77.04123IRFVT634.78WaterC~18~-FA99.53125KSSAYSLQMGATAIKQVKKLFKKWGW2985.59WaterC~18~-FA66.39132LFSLVLAG819.01Water+33% DMSOC~18~-FA96.92133LFVVTLVG847.06Water+60% DMSOC~18~-FA97.74134LPFEF651.76Water+50% DMSOC~18~-FA17.17135LPFEH641.72WaterC~18~-FA94.23137LVTLVFV790.01Water+50% DMSOC~18~-FA84.02138MAGNSSNFIHKIKQIFTHR2229.59Water+17% DMSOC~18~-FA81.90140MKAEH614.72WaterC~18~-FA66.91143MPFEF669.79WaterC~18~-FA86.24146NEVPFEF880.95WaterC~18~-FA99.90147NGWNN603.59WaterC~18~-FA94.53148YSTCDFIM, thiolacton linkage between C4 and M8961.25Water+50% DMSOC~18~-FA44.40151NNGNN531.48WaterC~18~-TFA96.79152NNNWNNN888.85WaterC~18~-FA98.42153NNWGN603.59WaterC~18~-FA99.10154NNWNG603.59WaterC~18~-FA99.33155NWN432.44WaterC~18~-FA98.40156FNTIP589.69WaterC~18~-FA99.27157FNTWP662.75WaterC~18~-FA99.23160QKGMY625.74WaterC~18~-FA99.04162QRGMI603.74WaterC~18~-FA94.36164SDLPFEH843.89WaterC~18~-FA91.37165SDMPFEF871.96WaterC~18~-FA99.44166SGSLSTFFLLFNRSFTQALGK2321.66WaterC~18~-FA92.99174SGSLSTFFRLFNRSFTQALG2236.52WaterC~18~-FA97.41176SGSLSTFFRLFNRSFTQALGK2364.69WaterC~18~-FA98.96177SGSLSTFFRLFNRSFTQALGKIR2634.04WaterC~18~-FA55.68180SGSLSTFFRLFNRSQTQALGK2345.65WaterC~18~-FA99.06184SIFTLVA749.90Water+33% DMSOC~18~-FA93.17186SKDYN625.64WaterC~18~-TFA92.88188SLSTFFRLFNFSFTQALG2083.37Water+33% DMSOC~18~-FA85.61191SRKAT561.64WaterC~18~-TFA78.31192SRNAT547.57WaterOrganic Acid81.74193SRNVT575.62WaterC~18~-TFA81.49206SYPGWSW881.94WaterC~18~-FA99.45207TAGPAIRASVKQCQKTLKATRLFTVSCKGKNGCK3595.31WaterC~18~-FA32.42208TNRNYGKPNKDIGTCIWSGFRHC2668.01WaterC~18~-FA89.19210VAVLVLGA740.94Water+33% DMSOC~18~-FA92.98212VPFEF637.73WaterC~18~-FA97.65214WPFAHWPWQYPR1670.89WaterC~18~-FA58.94215FNTWPKY954.10WaterC~18~-FA95.52218YNPCSNYL, thiolacton linkage between C4 and L8955.18Water+50% DMSOC~18~-FA16.87[^2][^3]

2.2. Sample preparation {#s0020}
-----------------------

0.5--1 mg of each lyophilized, linear peptide was dissolved in water or a mixture of water and DMSO, depending on the calculated log *P* values and the solubility in water, to obtain a concentration of approximately 1.0 mg/mL ([Table 1](#t0005){ref-type="table"}). The quantity of DMSO used was determined experimentally, by adding DMSO stepwise to the peptide-water suspension until no more precipitate was observed. The dissolved peptides were stored at −35 °C. The cyclic peptides (*i.e*. ID5, 22, 32, 40, 71, 97, 107, 148 and 218) were dissolved in DMSO-water (50/50, V/V) to obtain a concentration of approximately 0.5 mg/mL.

2.3. HPLC and UPLC {#s0025}
------------------

### 2.3.1. QC purity profiling {#s0030}

Three LC systems were consecutively applied in the analysis. To avoid carry-over peaks, 50% acetonitrile in water was always used as needle wash.

Each peptide was first analyzed with the Acquity UPLC BEH300 C~18~ column. Sample compartment was kept at 5 °C (± 2 °C) and column was maintained at 30 °C (±2 °C). Injection volume was set at 2 µL for the linear and 5 µL for the cyclic peptides. Mobile phases consisted of 0.1% (m/V) formic acid in water (A) and 0.1% (m/V) formic acid in acetonitrile (B). A general linear gradient was applied running from 95% A to 20% A during 22 min, followed by returning to initial condition and re-equilibration with a flow rate set at 0.5 mL/min. Analysis was conducted using a Waters Acquity UPLC Class BioQuaternary Solvent Manager, a Waters Acquity Bio-sample Manager, combined with a Flow Through Needle and a Waters Acquity UPLC PDA (500 nL to 10 mm path length analytical flow cell) detector (Waters, Milford, MA, USA). Empower™ 2 software was employed for data acquisition and analysis. Peptides and related impurities were quantified by area-normalization at 210 nm, using a sampling rate of 20 points/s and a detector time constant of 0.1 s. A reporting threshold (*i.e*. 0.1% of main peak AUC in the UV chromatogram) and identification threshold (*i.e*. 0.5% of main peak AUC in the UV chromatogram) as stated in the European Pharmacopoeia were applied [@bib39]. Solvent and system peaks, observed in the blank (*i.e*. the solvent used to dissolve a certain peptide, [Table 1](#t0005){ref-type="table"}), were excluded.

If no retention of the peptides was observed using the Acquity UPLC BEH300 C~18~ column, peptides were analyzed with the Vydac Everest C~18~ column on a Waters Alliance 2695 HPLC apparatus equipped with a Waters 2695 Separations Module, combined with a Flow Through Needle, and a Waters 2996 Photodiode Array Detector with Empower™ 2 software for data acquisition. Mobile phases consisted of 0.1% (m/V) TFA in water (A) and 0.1% (m/V) TFA in acetonitrile (B). A general linear gradient was applied running from 95% A to 20% A during 30 min, followed by returning to initial condition and re-equilibration with a flow rate set at 1.0 mL/min. For peptide ID191, a slightly modified linear gradient was applied, *i.e*. running from 98% A to 80% A during 10 min, followed by returning to initial conditions and re-equilibration with a flow rate set at 1.0 mL/min. Sample compartment was kept at 5 °C (±2 °C) and column was maintained at 30 °C (±2 °C); 20 µL of the samples dissolved in suitable solvent composition were injected. UV detection was performed at 215 nm using a sample rate of 1.0 point/s combined with a detector time constant of 0.2 s. The flow rate was set to 1.0 mL/min. The peptide purity was quantified through normalization by calculating the area (UV) of the most abundant peak as a percentage of total peak areas.

Finally, peptides ID18, 51 and 192 were analyzed using a Grace Alltech Prevail Organic Acid column (250 mm×4.6 mm, 5 µm), using the same Waters Alliance 2695 HPLC equipment as used with the Vydac column. Mobile phases consisted of 10 mM phosphate buffer (pH 7) (A) and acetonitrile (B). A general linear gradient was applied running from 95% A to 60% A during 20 min, followed by returning to initial condition and re-equilibration with a flow rate set at 1.0 mL/min. Sample compartment was kept at 5 °C (±2 °C) and column maintained at 30 °C (±2 °C). 20 µL of the samples dissolved in suitable solvent composition were injected. UV detection was performed at 215 nm, using a sample rate of 1.0 point/s combined with a detector time constant of 0.2 s. The peptide purity was quantified through normalization by calculating the area (UV) of the most abundant peak as a percentage of total peak areas.

### 2.3.2. Identification of main LC peak and related impurities {#s0035}

Mass spectroscopic characterization was performed with a Thermo HPLC system consisting of a Waters 2487 dual *λ* absorbance UV/VIS-detector (UV at 215 nm), a Finnigan LCQ ion trap mass spectrometer with electrospray ionization (ESI) and Xcalibur™ software version 2.0 for data acquisition. The LC--MS equipment is yearly qualified using a tune solution and qualification solution according to the EDQM guideline [@bib40]. The tune solution consists of 100 µL 1.0 mg/mL caffeine (Sigma-Aldrich, Diegem, Belgium) in methanol, 15 µL 5 nmol/µL MRFA (Met-Arg-Phe-Ala) (Research Plus Inc., Atlantic City, NJ, USA) in 50/50 methanol/water (V/V), 2.5 mL 0.1% (V/V) Ultramark 1621 (Alfa Aesar, Karlsruhe, Germany) in acetonitrile, 50 µL glacial acetic acid (Riedel de Haen, Diegem, Belgium) and 2.34 mL of 50/50 methanol/water (V/V). The EDQM qualification solution consists of a 10.0 µg/mL reserpine (Flandria, Ghent, Belgium) solution in acidified methanol (*i.e*. 1% acetic acid in methanol (V/V)). The reserpine solution is infused in the mass spectrometer with a flow rate of 3 µL/min with a collision energy of 35.00 eV. The *m*/*z* value of 609.4 is selected as parent ion and the *m*/*z* range for the daughter ions is set to *m*/*z* 165.0-800.0. The obtained *m*/*z* values are compared with the acceptance criteria as set by the EDQM.

For the analysis of the quorum sensing peptides, column temperature was set at 30 °C (±2 °C) and samples were kept at room temperature. 20 µL of aqueous peptide solution was injected into the HPLC system and a flow rate of 1.0 mL/min was applied. All 15 selected quorum sensing peptides were analyzed using the Vydac Everest C~18~ column (250 mm×4.6 mm, 5 µm). Mobile phases consisted of 0.1% (m/V) formic acid in water (A) and 0.1% (m/V) formic acid in acetonitrile (B) with a flow rate of 1.00 mL/min. An isocratic period consisting of 95% A during 5 min was maintained, followed by a linear gradient running from 95% A to 40% A in 60 min and returning to the initial conditions and re-equilibration afterwards. The ion transfer capillary was operated at 250 °C, nitrogen was used as sheath gas (80 arbitrary units corresponding to 1.2 L/min) and helium as auxiliary gas (20 arbitrary units corresponding to 0.2 L/min). The spray voltage was 4.50 kV and the capillary voltage was 46 V. MS^1^ (100--2000 *m*/*z*) and MS^2^ (data dependent, *i.e*. highest abundant MS^1^ *m*/*z* value for MS^2^) data were obtained. All *m*/*z* values possessing an abundance higher than 25% in the according MS^1^ spectrum were subject to identification via their respective MS^2^ fragmentation pattern. Theoretical MS^2^ fragmentation patterns of the peptides were calculated *in silico* with ProteinProspector [@bib41] (University of California, San Francisco, CA, USA). The proposed sequences of the related impurities were confirmed using the ProteinProspector generated MS^2^ spectra. The nomenclature originally proposed by [@bib42] [@bib42] was used to annotate MS^2^ fragments.

3. Results and discussion {#s0040}
=========================

3.1. Quorum sensing peptide analysis flow chart {#s0045}
-----------------------------------------------

To determine the purity of the quorum sensing peptides, we developed a UPLC/HPLC-analysis flow chart ([Fig. 1](#f0005){ref-type="fig"}). Each peptide was analyzed first with the Acquity UPLC BEH300 C~18~ column, using the method described above. A C~18~ column with a 0.1% (m/V) formic acid in water/acetonitrile gradient is widely used for peptide analysis and was therefore selected as the initial method of analysis. If no retention of the peptides was observed, the peptides were analyzed with the Vydac Everest C~18~ column with TFA as ion-pairing reagent, which is known to have a narrowing effect on peak width and an increased retention. Finally, if no retention was observed with the aforementioned columns, the Prevail Organic Acid column (mobile phase of pH 7) with a 10 mM phosphate buffered water/acetonitrile gradient was used for peptide quality control. Previous experience indicated that peptides which had no retention using standard C~18~ peptide columns might have appropriate retention using a polar-embedded column for highly hydrophilic compounds, like the Prevail Organic Acid column.Fig. 1(U)HPLC column flow chart for quorum sensing peptides analysis.

3.2. QC purity assay {#s0050}
--------------------

Despite a requested purity of at least 95.0%, only 43 out of 98 peptides met these purity specifications ([Fig. 2](#f0010){ref-type="fig"}). However, all the 98 peptides were accompanied by a certificate of analysis stating at least 95.0% purity. Our QC analysis upon arrival showed purity levels sometimes far below the demanded purity level ([Table 1](#t0005){ref-type="table"}). In [Fig. 3](#f0015){ref-type="fig"}, the chromatogram of ID76, as provided by the supplier on the certificate of analysis versus our QC analysis, is given. The mobile phases of the supplier consisted of 0.1% (m/V) TFA in acetonitrile (A) and 0.1% (m/V) TFA in water (B). A general linear gradient was applied running from 22% A to 47% A during 22 min with a Kromasil C~18~-5 (250 mm×4.6 mm, 5 µm) column with quantification at 220 nm. The peptide was analyzed in our laboratory with the Acquity UPLC BEH300 C~18~ column, using the operational details as described above.Fig. 2Purity levels of quorum sensing peptides determined by in-house QC.Fig. 3The in-house QC control shows a distinct difference in peptide purity. (A) Chromatogram of supplier; Kromasil C~18~-5 (250 mm×4.6 mm, 5 µm), quantification at 220 nm; (B) chromatogram of in-house QC; Vydac Everest C~18~ column (250 mm×4.6 mm, 5 µm), quantification at 210 nm.

The method applied by the supplier clearly lacked selectivity to determine the purity level of the peptide. We demonstrated the necessity of a reliable QC method, *i.e*. the need of a suitable chromatographic system to analyze peptide purity. The supplier claimed ≥95.0% purity using its system, where we determined a purity level of 80.6%.

Especially the cyclic peptides (*n*=9) were characterized by low purity levels: none of the peptides had a purity exceeding 90.0%. Of all cyclic peptides, 1 peptide had a purity between 80.0% and 90.0%, whereas the other 8 had purity levels below 80.0%. Nevertheless, each of these peptides was accompanied by a certificate of analysis stating a purity of at least 95.0%. After communication with the suppliers, they revealed that they were unable to produce these cyclic peptides at the requested purity level.

3.3. Identification of related impurities {#s0055}
-----------------------------------------

A set of 15 peptides with varying purities was selected to determine the identity of the impurities ([Table 1](#t0005){ref-type="table"}, depicted in red). The main peak was characterized as the desired peptide for 14 out of 15 peptides. The main peak from peptide ID25 was not the requested amino acid sequence. Instead of CVFSLFKKCN, a peptide with a mass difference of −2.1 Da compared with the requested peptide sequence was noted. Therefore, the formation of a disulfide bond (and thus cyclisation) between C~1~ and C~9~ is suggested. Because sulfur-containing amino acids are prone to oxidation [@bib43], a spontaneous cyclisation is suspected for this peptide ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4TIC and UV chromatogram (A), MS^1^ (B) and MS^2^ (C) spectra of the related impurity C~1~VFSLFKKC~9~N (disulfide bond between C~1~ and C~9~) of peptide ID25 at a retention time of 23.47 min with appointed isotopic mass patterns and b- and y-fragmentation are allocated.

The MS^1^ spectrum of a related peptide impurity of peptide ID134 (retention time of 29.75 min) showed an impurity with a monoisotopic mass of 666.22 Da ([Fig. 5](#f0025){ref-type="fig"}). The difference with the monoisotopic mass of the requested peptide sequence (LPFEF) amounted to 14.04 Da, a mass difference that could be associated with the addition of a methyl group. The MS^2^ fragmentation pattern of the related peptide impurity ([Fig. 5](#f0025){ref-type="fig"}C) showed a difference of +14 Da with the requested peptide sequence fragmentation pattern at b~4~, y~2~-H~2~O, y~4~, MH-H~2~0, while the b~3~ fragment of requested peptide and related impurity were the same, thus suggesting the addition of a methyl group to Glu4.Fig. 5TIC and UV chromatogram (A), MS^1^ (B) and MS^2^ (C) spectra of the related impurity LPFE(methyl)F of peptide ID134 at a retention time of 29.75 min with appointed isotopic mass patterns and b- and y-fragment allocation.

A related impurity of peptide ID82 (retention time 9.34 min) possessed an *m*/*z* value of 621.14 ([Fig. 6](#f0030){ref-type="fig"}). Compared with the desired peptide, *i.e*. NTIPKY, there was a mass difference of 114.02 Da, a mass difference which could be bridged by the deletion of Asn1. The suggested sequence TIPKY was confirmed by the MS^2^ spectrum in [Fig. 6](#f0030){ref-type="fig"}C. On the other hand, we also demonstrated a related impurity characterized by the incorporation of an additional amino acid at the C-terminus of peptide ID121 (retention time 35.70 min) ([Fig. 7](#f0035){ref-type="fig"}). The MS^2^ spectrum ([Fig. 7](#f0035){ref-type="fig"}C) confirmed the addition of an extra Trp residue at the C-terminus of peptide ID121, thus resulting in the related impurity ILSGAPCIPWW. Another example of a related peptide impurity was the combination of both deleted and additionally inserted amino acids in the desired peptide sequence. In [Fig. 8](#f0040){ref-type="fig"}, such an example is given: ILSGAPCIPPPP is a related impurity of peptide ID121 and lacks the C-terminal Trp residue, but is characterized by 3 additional Pro residues at the C-terminus.Fig. 6TIC and UV chromatogram (A), MS^1^ (B) and MS^2^ (C) spectra of the related impurity TIPKY of peptide ID82 at a retention time of 9.59 min with appointed isotopic mass patterns and b- and y-fragment allocation.Fig. 7TIC and UV chromatogram (A), MS^1^ (B) and MS^2^ (C) spectra of the related impurity ILSGAPCIPWW of peptide ID121 at a retention time of 35.70 min with appointed isotopic mass patterns and b- and y-fragment allocation.Fig. 8TIC and UV chromatogram (A), MS^1^ (B) and MS^2^ (C) spectra of the related impurity ILSGAPCIPPPP of peptide ID121 at a retention time of 33.55 min with appointed isotopic mass patterns and b- and y-fragment allocation.

In total, 84 impurities ([Table 2](#t0010){ref-type="table"}) were observed and 73% could be assigned a structure related to the requested peptide by means of MS^2^. Analysis of these identified impurities revealed a high abundance of impurities with at least one deletion (*i.e*. in 74% of all identified impurities is involved) ([Fig. 9](#f0045){ref-type="fig"}). Inappropriate deletion of blocking groups during synthesis results in such sequences, thereby lacking at least 1 amino acid [@bib20], [@bib44]. A minority of the observed peptide impurities were characterized by the incorporation of additional amino acids. During synthesis, an excess of amino acid equivalents used to assure a maximum coupling efficiency might result in the incorporation of additional amino acids [@bib20], [@bib45]. Impurities can also be a combination of alteration types, *e.g*. one or more desired amino acid(s) might be missing at the N-terminus whilst at the C-terminus additional amino acid(s) are incorporated.Fig. 9Types of related peptide impurities found in the 61 experimentally determined sequences.Table 2Overview of the observed peptides (blue) and impurities (purple).![](fx1.gif)![](fx2.gif)[^4][^5][^6][^7]

4. Conclusions {#s0060}
==============

In conclusion, "purified" synthetic peptides still contain a considerable amount and wide variety of related impurities, with peptides missing amino acid(s) being the most prominent. As a consequence, a thorough in-house quality characterization of peptides, already used in basic biomedical research, is mandatory. Remarkably, there is a large discrepancy between the certificates of analysis provided by the suppliers and the in-house quality control, which can at least partly be explained by the methods used. Finally, researchers should also be aware that the main peak observed in the chromatogram might be an impurity instead of the requested peptide; hence MS is requested in this QC.
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[^1]: These authors contributed equally to this work.

[^2]: C~18~-FA: acquity UPLC BEH 300 C~18~ column (100 mm×2.1 mm, 1.7 µm). C~18~-TFA: Vydac Everest C~18~ column (250 mm×4.6 mm, 5 µm). Organic acid: Grace Alltech Prevail Organic Acid column (250 mm×4.6 mm, 5 µm).

[^3]: Purity assigned based on UV chromatogram with internal normalization to the most abundant peak.

[^4]: ^1^Purity assigned based on UV chromatogram with internal normalization to the most abundant peak.

[^5]: ^2^The peptide C~1~VFSLFKKC~9~N (disulfide bond between C~1~ and C~9~) was the most abundant peak and was not the desired sequence.

[^6]: ^3^Structural deviations are defined as follows: (a) Chemical modifications of an amino acid are depicted in between brackets following the modified amino acid; (b) **X** signals a "semi-identified" impurity with already part of the peptide sequence allocated in the MS^2^ fragmentation pattern.

[^7]: ^4^Solely observed in UV spectrum, no signal in TIC.
